1st Quarter - Report

AMERICAN SOCIETY OF CONSULTANT PHARMACISTS for AMERICAN SOCIETY OF CONSULTANT PHARMACISTS

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$40,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Mar 24, 2017 $40,000 Replaced
1st Quarter - Termination Jul 20, 2017 $40,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Pharmacist Provider Status

LobbyistCovered position, as disclosed
PETER RANKIN Director of Policy and Advocacy

Contacted: Food & Drug Administration (FDA); Drug Enforcement Administration (DEA); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Pharmacist provider status H.R 592/S.109

LobbyistCovered position, as disclosed
PETER RANKIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Drug Enforcement Administration (DEA)

Bills named: S. 109 (115th), H.R. 592 (115th)

Pharmacy PHA

Pharmacy provider status

LobbyistCovered position, as disclosed
PETER RANKIN —

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Drug Enforcement Administration (DEA); HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.